Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 09, 2024 16:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
July 03, 2024 22:00 ET
|
Bragar Eagel & Squire
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Assertio Holdings, Inc....
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 06, 2024 16:05 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
June 05, 2024 08:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Assertio Announces the Appointment of Brendan P. O’Grady as New CEO
May 29, 2024 07:00 ET
|
Assertio Holdings, Inc.
Assertio appoints Brendan P. O'Grady as CEO
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
May 17, 2024 09:15 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering...
Assertio to Participate in AGP Healthcare Conference on May 21
May 16, 2024 09:16 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering...
Assertio Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET
|
Assertio Holdings, Inc.
First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to...
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
April 25, 2024 08:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...
Sig Kirk Joins Assertio Board of Directors
April 03, 2024 08:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities...